Video

Video

Working with patient associations: What is the key to a positive interaction?

https://www.youtube.com/watch?v=R65yKqxo4zQWhat rare disease patients and families want is a simpler life.Discover here what makes the relationship between the members of the patients’ association and a company work so well. Check...

Video

How a patient association gave rise to a company

Patients insights Rare disease

A patient association in rare diseases is first and foremost families who all have one thing in common: they need...

Subscribe to our newsletter

Rare disease clinical research: it is time to tackle what...

The client’s voice: why they consistently choose Kayentis

Why you should join Kayentis

Rethinking pediatric clinical trials: guidelines from pediatric experts

Overcoming challenges in long-lasting pediatric clinical trials – Insights from...

Tackling the specificities of NASH/MASH clinical trials

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20

Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA